Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4331840 | 0.89 | POLB (0.59) | POLBSMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL27946037 | 0.88 | POLB (0.58) | POLBSMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL20346311 | 0.87 | MAPT (0.48) | POLBSMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL7261188 | 0.87 | POLB (0.65) | POLBSMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL8795832 | 0.84 | LMNA (0.48) | POLBMEN1KMT2AMAPTLMNA | |
| SCHEMBL7260513 | 0.84 | POLB (0.61) | POLBSMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL1409033 | 0.83 | MMP8 (0.51) | POLBSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL20346315 | 0.83 | LMNA (0.47) | POLBSMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL8796147 | 0.83 | CA12 (0.48) | POLBSMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL8796085 | 0.83 | CA12 (0.48) | POLBSMN1; SMN2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11485725-B2 | Derivatives of piperlongumine and uses thereof | AURANSA INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-20210198235-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2021-07-01 | — | — | US | disclosed |
| US-20210198235-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2021-07-01 | — | — | US | disclosed |
| US-20200377510-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200377510-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2020-12-03 | — | — | US | disclosed |
| EP-2928457-B1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2020-08-12 | — | — | EP | disclosed |
| CN-105283177-B | Cyclopropylamine derivatives useful as inhibitors of histone demethylase KDM1A | 欧洲肿瘤研究所有限责任公司 | 2020-07-24 | — | — | CN | disclosed |
| WO-2019103897-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| US-9944589-B2 | Cycloproplyamine derivatives useful as inhibitors of histone demethylases KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2018-04-17 | — | — | US | disclosed |
| US-20150315126-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2015-11-05 | — | — | US | disclosed |
| US-5436369-A | Alicyclic phospholipase A2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| US-5385942-A | Therapy of cirrhosis, liver disorders | EISAI CO., LTD. (JP) | 1995-01-31 | — | — | US | disclosed |
| EP-0629604-A2 | Alicyclic phospholipase A2 inhibitors | Bristol-Myers Company (US) | 1994-12-21 | — | — | EP | disclosed |
| EP-0344979-B1 | Alfa-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1994-11-09 | — | — | EP | disclosed |
| US-5210239-A | Treatment of Hepatic Diseases | EISAI CO., LTD. (JP) | 1993-05-11 | — | — | US | disclosed |
| EP-0419905-A2 | Quinone derivatives and pharmacological use | Eisai Co., Ltd. (JP) | 1991-04-03 | — | — | EP | disclosed |
| US-4963547-A | HYPOTENSIVE AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1990-10-16 | — | — | US | disclosed |
| WO-1989012054-A1 | alpha-ADRENERGIC RECEPTOR ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-12-14 | — | — | WO | disclosed |
| WO-1989012050-A1 | alpha-ADRENERGIC RECEPTOR ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-12-14 | — | — | WO | disclosed |
| EP-0344979-A2 | Alfa-adrenergic receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377510-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | SHARPIN, PIR, THPO | POLB 3663/4885SMN1; SMN2 4475/4885MEN1 1134/4885 |
| US-20150315126-A1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | KDM1A, KDM1B, KDM2A | POLB 1964/4885SMN1; SMN2 2921/4885MEN1 3773/4885 |
| US-20210198235-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | THPO, PIR, PAK6 | POLB 3446/4885SMN1; SMN2 4277/4885MEN1 1394/4885 |
| US-11485725-B2 | Derivatives of piperlongumine and uses thereof | PIR, THPO, DHPS | POLB 3700/4885SMN1; SMN2 4366/4885MEN1 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.